← Leaderboards
Donald M Miller
University Of Louisville
$9,881,293
Attributed
$11,711,795
Total exposure
17
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–17$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$35,942,675 · 18
CDC$0 · 1
By mechanism
P20$25,763,768 · 12
P30$6,357,660 · 2
U01$2,994,875 · 1
R01$458,379 · 3
R21$367,993 · 1
Top collaborators
- Paula J Bates3 shared
- Eugene Krentsel2 shared
Most similar at University Of Louisville
Same institution · by research overlap
- John O Trent$4,178,948
- Yury Gerasimenko$1,397,593
- Paula J Bates$4,472,619
- (patricia) Jill Ward$1,447,224
- Eugene Krentsel$2,311,090
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthFundingCenters Of Research ExcellenceFacultyResearch PersonnelMemberMolecular TargetProgramsGrantEnsureSuccessAntineoplastic AgentsClinical TrialsUniversitiesResearch InfrastructureResourcesGrowthCancer CenterTranslational ResearchTranslatingLeadershipCore FacilityDrug DevelopmentInstitution
Grant awards (45)
Molecular Targets Phase III CoBRE$1,036,424
P30 · FY2017 · GM · contact PI
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship$996,487
U01 · FY2017 · HL
Common hTERT Promoter Mutations Represent a Novel Therapeutic Target$200,970
R21 · FY2017 · CA · contact PI
ADMINISTRATIVE CORE$196,582
P30 · FY2017 · GM · contact PI
Molecular Targets Phase III CoBRE$1,052,312
P30 · FY2016 · GM · contact PI
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship$999,194
U01 · FY2016 · HL
ADMINISTRATIVE CORE$196,658
P30 · FY2016 · GM · contact PI
Common hTERT Promoter Mutations Represent a Novel Therapeutic Target$167,023
R21 · FY2016 · CA · contact PI
Molecular Targets Phase III CoBRE$1,067,488
P30 · FY2015 · GM · contact PI
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship$999,194
U01 · FY2015 · HL
ADMINISTRATIVE CORE$196,658
P30 · FY2015 · GM · contact PI
Molecular Targets Phase III CoBRE$1,097,222
P30 · FY2014 · GM · contact PI
ADMINISTRATIVE CORE$196,658
P30 · FY2014 · GM · contact PI
Molecular Targets Phase III CoBRE$1,121,000
P30 · FY2013 · GM · contact PI
ADMINISTRATIVE CORE$196,658
P30 · FY2013 · GM · contact PI
Molecular Targets COBRE$2,023,789
P20 · FY2012 · GM · contact PI
Molecular Targets COBRE$2,028,469
P20 · FY2011 · RR · contact PI
COBRE: LOUISVILLE RES FOUND INC: CORE A:ADMINISTRATIVE CORE$369,769
P20 · FY2011 · RR · contact PI
Molecular Targets COBRE$2,048,959
P20 · FY2010 · RR · contact PI
COBRE: LOUISVILLE RES FOUND INC: CORE A:ADMINISTRATIVE CORE$373,504
P20 · FY2010 · RR · contact PI
Molecular Targets COBRE$994,005
P20 · FY2009 · RR · contact PI
Molecular Targets COBRE$759,342
P20 · FY2009 · RR · contact PI
Molecular Targets COBRE$192,104
P20 · FY2009 · RR · contact PI
COBRE: LOUISVILLE RES FOUND INC: CORE A:ADMINISTRATIVE CORE$181,197
P20 · FY2009 · RR · contact PI
Molecular Targets COBRE$1,978,806
P20 · FY2008 · RR · contact PI
COBRE: LOUISVILLE RES FOUND INC: CORE A:ADMINISTRATIVE CORE$439,154
P20 · FY2008 · RR · contact PI
Center of Biomedical Research Excellence in Molecular Targets$1,993,338
P20 · FY2007 · RR · contact PI
COBRE: LOUISVILLE RES FOUND INC: CORE A:ADMINISTRATIVE CORE$462,157
P20 · FY2007 · RR · contact PI
Center of Biomedical Research Excellence in Molecular *$2,052,871
P20 · FY2006 · RR · contact PI
COBRE: LOUISVILLE RES FOUND INC: CORE A:ADMINISTRATIVE CORE$310,456
P20 · FY2006 · RR · contact PI
James Graham Brown P20 Application$273,456
P20 · FY2006 · CA · contact PI
Center of Biomedical Research Excellence in Molecular *$2,102,173
P20 · FY2005 · RR
COBRE: LOUISVILLE RES FOUND INC: ALTERATION &RENOVATION$544,567
P20 · FY2005 · RR
COBRE: LOUISVILLE RES FOUND INC: CORE A:ADMINISTRATIVE CORE$296,890
P20 · FY2005 · RR
James Graham Brown P20 Application$109,668
P20 · FY2005 · CA
Agri-Pharmaceutical Cancer Therapeutics$0
R01 · FY2005 · DP
Biomedical Research Excellence in Molecular Targets$2,102,273
P20 · FY2004 · RR
CORE--ALTERATION &RENOVATION$403,656
P20 · FY2004 · RR
COBRE: LOUISVILLE RES FOUND INC: CORE A:ADMINISTRATIVE CORE$345,572
P20 · FY2004 · RR
James Graham Brown P20 Application$265,491
P20 · FY2004 · CA
Center of Biomedical Research Excellence$2,604,094
P20 · FY2003 · RR
James Graham Brown P20 Application$257,758
P20 · FY2003 · CA
James Graham Brown P20 Application$250,250
P20 · FY2002 · CA
MODULATION OF C-MYC EXPRESSION BY TRIPLEX FORMATION$237,008
R01 · FY2000 · CA
TRIPLEX BASED INHIBITION OF DHFR AND CYCLIN DL$221,371
R01 · FY2000 · CA